CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: June 24, 2011
Result type: Reports
Project Number: SF0239-000
Product Line: Reimbursement Review

Generic Name: Rivaroxaban

Brand Name: Xarelto

Manufacturer: Bayer Inc.

Therapeutic Area: Venous thromboembolism, prevention

Indications: Thromboembolism (venous) prevention

Submission Type: Request For Advice

Project Status: Complete